National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Last Modified: 4/24/2009     First Published: 5/5/2006  
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Phase III Randomized Study of Imatinib Mesylate With Versus Without Bevacizumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, TreatmentActive18 and overNCISWOG-S0502
S0502, CALGB-S0502, CAN-NCIC-S0502, NCT00324987

Special Category: NCI - CMS pilot project trial, NCI Web site featured trial, CTSU trial

Objectives

  1. Compare the progression-free survival of patients with metastatic or unresectable gastrointestinal stromal tumor treated with imatinib mesylate with vs without bevacizumab.
  2. Compare the response probabilities (in patients with measurable disease) and overall survival rates in patients treated with these regimens.
  3. Compare the frequency and severity of toxicities associated with these regimens in these patients.
  4. Correlate soluble vascular endothelial growth factor (VEGF), VEGF-D, VEGF receptor (VEGFR)-1, VEGFR-2, angiopoietin-2, platelet-derived growth factor receptor (PDGFR)-AA and PDGFR-BB levels, positron-emission tomography imaging, and immunohistochemistry for p16, VEGF, and VEGFR with kinase mutation status and clinical outcomes.
  5. Examine the pharmacokinetics of imatinib mesylate with single nucleotide polymorphisms involving the ABCG2 and CYP3A4 genes, as well as other genes that are reported to influence the absorption, distribution, metabolism, and elimination of imatinib mesylate.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed gastrointestinal stromal tumor (GIST)
    • Metastatic or unresectable disease
      • Determined to be unresectable for cure


  • Measurable and/or nonmeasurable disease


  • No known brain metastasis


Prior/Concurrent Therapy:

  • Recovered from prior therapy
  • At least 28 days since prior chemotherapy
  • At least 28 days since prior radiotherapy
    • Evidence of progressive disease within the radiation field or disease outside the radiation field
  • No prior imatinib mesylate, bevacizumab, or other agents targeting KIT, vascular endothelial growth factor (VEGF), VEGF receptor, or platelet-derived growth factor receptor (PDGFR) for advanced disease
    • These agents may have been used in the adjuvant setting provided no recurrence for ≥ 12 months after completion of therapy
  • More than 28 days since prior major surgery or open biopsy
  • No anticipated need for major surgery
  • More than 7 days since prior fine-needle aspiration or core biopsies
  • More than 7 days since prior procedure to place a portacath
  • No other concurrent anticancer biologic agents, chemotherapy, radiotherapy, or any other anticancer agents
  • No concurrent therapeutic warfarin for anticoagulation
    • Concurrent low-molecular weight heparin or other agents for therapeutic anticoagulation or mini-dose warfarin for prophylaxis allowed
  • No other concurrent investigational agents

Patient Characteristics:

  • Zubrod performance status 0-3
  • Platelet count ≥ 100,000/mm3
  • Absolute neutrophil count ≥ 1,000/mm3
  • Hemoglobin ≥ 9 g/dL (transfusion allowed)
  • Bilirubin ≤ 2.0 times upper limit of normal (ULN)
  • SGOT/SGPT ≤ 2.5 times ULN (5 times ULN with liver involvement)
  • Creatinine ≤ 1.5 times ULN
  • Urine protein:creatinine ratio < 1
  • INR ≤ 1.5
  • PTT normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for up to 6 months after completion of study treatment
  • No cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina within the past 6 months
  • No serious cardiac arrhythmia requiring medication
  • No New York Heart Association class II-IV congestive heart failure
  • No clinically significant peripheral vascular disease
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
  • No contraindication to oral medications (e.g., severe dysphagia)
    • G- or J-tubes allowed
  • No history of hypertension unless well controlled (i.e., blood pressure < 160/90 mm Hg) and on a stable regimen of antihypertensive therapy
  • No serious nonhealing wound, ulcer, or bone fracture
  • No other prior malignancy except for any of the following:
    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer
    • Adequately treated stage I or II cancer that is currently in complete remission
    • Any other cancer for which the patient has been disease free for ≥ 5 years
  • No significant traumatic injury in the past 28 days

Expected Enrollment

572

A total of 572 patients will be accrued for this study.

Outcomes

Primary Outcome(s)

Progression-free survival as measured by Cox Proportional Hazards Model at 6 months

Secondary Outcome(s)

Overall survival as measured by Cox Proportional Hazards Model
Response probabilities in subset of patients with measurable disease
Frequency and severity of toxicities as measured by NCI CTCAE v3.0
Correlation between growth factor/receptor levels, positron-emission tomography imaging, and immunohistochemistry for p16, VEGF, and VEGFR with kinase mutation status and clinical outcomes
Pharmacokinetics of imatinib mesylate

Outline

This is a randomized, multicenter study. Patients are stratified according to Zubrod performance status (0 vs 1-3) and disease status (measurable vs non-measurable). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral imatinib mesylate once daily on days 1-21 and bevacizumab IV over 30-90 minutes on day 1.


  • Arm II: Patients receive oral imatinib mesylate once daily on days 1-21.


In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood is obtained at baseline, periodically during study treatment, and at disease progression. Blood is analyzed for angiogenesis-related soluble factors, kinase genotyping, pharmacokinetics, and pharmacogenomics.

After completion of study treatment, patients are followed periodically for up to 7 years.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Blanke, MD, FACP, Protocol chair
Ph: 604-877-6098 ext. 2738
Email: cblanke@bccancer.bc.ca
Margaret von Mehren, MD, Protocol co-chair
Ph: 215-728-3545; 888-369-2427

Cancer and Leukemia Group B

George Demetri, MD, Protocol chair
Ph: 617-632-3985; 866-790-4500
Email: gdemetri@partners.org

NCIC-Clinical Trials Group

Vivien Bramwell, MB, BS, PhD, FRCP, Protocol chair
Ph: 403-521-3707

Trial Sites

U.S.A.
Alabama
  Mobile
 Providence Cancer Center at Providence Hospital
 Paul Schwarzenberger, MD
Ph: 251-544-1013
California
  Burbank
 Providence Saint Joseph Medical Center - Burbank
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  Los Angeles
 USC/Norris Comprehensive Cancer Center and Hospital
 Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital
Ph: 323-865-0451
District of Columbia
  Washington
 Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
 Clinical Trials Office - Lombardi Comprehensive Cancer Center
Ph: 202-444-0381
Georgia
  Gainesville
 Northeast Georgia Medical Center
 Charles Nash, MD
Ph: 770-297-5700
  Savannah
 Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
 Clinical Trials Office - Curtis and Elizabeth Anderson Cancer Institute
Ph: 912-350-8568
  Valdosta
 Pearlman Comprehensive Cancer Center at South Georgia Medical Center
 Jeffrey Hoy, MD
Ph: 229-259-4628
Illinois
  Aurora
 Rush-Copley Cancer Care Center
 Kendrith Rowland, MD
Ph: 217-383-3019
  Chicago
 John H. Stroger, Jr. Hospital of Cook County
 Michael Mullane
Ph: 312-864-3200
 Resurrection Medical Center
 Christopher Rose, MD
Ph: 847-965-3200
 University of Chicago Cancer Research Center
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
  Decatur
 Decatur Memorial Hospital Cancer Care Institute
 Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute
Ph: 217-876-6601
  Joliet
 Joliet Oncology-Hematology Associates, Limited - West
 Kendrith Rowland, MD
Ph: 217-383-3019
  La Grange
 La Grange Memorial Hospital
 Clinical Trials Office - La Grange Memorial Hospital
Ph: 630-856-7526
  Springfield
 Regional Cancer Center at Memorial Medical Center
 Clinical Trials Office - Regional Cancer Center at Memorial Medical Center
Ph: 217-788-4233
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Clinical Trials Office - Carle Cancer Center
Ph: 800-446-5532
 CCOP - Carle Cancer Center
 Clinical Trials Office - CCOP - Carle Cancer Center
Ph: 800-446-5532
Indiana
  Beech Grove
 St. Francis Hospital and Health Centers - Beech Grove Campus
 Howard Gross, MD
Ph: 937-832-1093
  Michigan City
 Saint Anthony Memorial Health Centers
 Kendrith Rowland, MD
Ph: 217-383-3019
  Richmond
 Reid Hospital & Health Care Services
 Howard Gross, MD
Ph: 937-832-1093
Iowa
  Ames
 McFarland Clinic, PC
 Clinical Trials Office - McFarland Clinic, PC
Ph: 515-239-2621
  Davenport
 Genesis Medical Center - West Campus
 George Kovach, MD
Ph: 563-421-1960
 Genesis Regional Cancer Center at Genesis Medical Center
 George Kovach, MD
Ph: 563-421-1960
  Des Moines
 CCOP - Iowa Oncology Research Association
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 John Stoddard Cancer Center at Iowa Lutheran Hospital
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital
Ph: 515-241-8704
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center
Ph: 515-241-6727
 Medical Oncology and Hematology Associates at John Stoddard Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Medical Oncology and Hematology Associates at Mercy Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Mercy Capitol Hospital
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
  Sioux City
 Mercy Medical Center - Sioux City
 Donald Wender, MD, PhD
Ph: 712-252-0088
 Siouxland Hematology-Oncology Associates, LLP
 Donald Wender, MD, PhD
Ph: 712-252-0088
 St. Luke's Regional Medical Center
 Donald Wender, MD, PhD
Ph: 712-252-0088
Kansas
  Chanute
 Cancer Center of Kansas, PA - Chanute
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Dodge City
 Cancer Center of Kansas, PA - Dodge City
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  El Dorado
 Cancer Center of Kansas, PA - El Dorado
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Fort Scott
 Cancer Center of Kansas - Fort Scott
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Independence
 Cancer Center of Kansas-Independence
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Kingman
 Cancer Center of Kansas, PA - Kingman
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Lawrence
 Lawrence Memorial Hospital
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Liberal
 Southwest Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Newton
 Cancer Center of Kansas, PA - Newton
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Parsons
 Cancer Center of Kansas, PA - Parsons
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Pratt
 Cancer Center of Kansas, PA - Pratt
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Salina
 Cancer Center of Kansas, PA - Salina
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Tammy Walker Cancer Center at Salina Regional Health Center
 William Cathcart-Rake, MD
Ph: 785-452-4860
  Wellington
 Cancer Center of Kansas, PA - Wellington
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Wichita
 Associates in Womens Health, PA - North Review
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Medical Arts Tower
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 CCOP - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Via Christi Cancer Center at Via Christi Regional Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Winfield
 Cancer Center of Kansas, PA - Winfield
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
Michigan
  Adrian
 Hickman Cancer Center at Bixby Medical Center
 Clinical Trials Office - Hickman Cancer Center at Bixby Medical Center
Ph: 517-265-0116
  Ann Arbor
 CCOP - Michigan Cancer Research Consortium
 Philip Stella, MD
Ph: 734-712-1000
 Saint Joseph Mercy Cancer Center
 Philip Stella, MD
Ph: 734-712-1000
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Clinical Trials Office - Oakwood Cancer Center at Oakwood Hospital and Medical Center
Ph: 313-593-8090
  Flint
 Genesys Hurley Cancer Institute
 Clinical Trials Office - Genesys Hurley Cancer Institute
Ph: 810-762-8057
 Hurley Medical Center
 Clinical Trials Office - Hurley Medical Center
Ph: 810-762-8057
  Grosse Pointe Woods
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Clincial Trials Office - Van Elslander Cancer Center at St. John Hospital and Medical Center
Ph: 313-343-3166
  Jackson
 Foote Memorial Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Lambertville
 Haematology-Oncology Associates of Ohio and Michigan, PC
 Paul Schaefer, MD
Ph: 419-479-5605
  Lansing
 Sparrow Regional Cancer Center
 Clinical Trials Office - Sparrow Regional Cancer Center
Ph: 517-364-2890
  Livonia
 St. Mary Mercy Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Monroe
 Community Cancer Center of Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
 Mercy Memorial Hospital - Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
  Pontiac
 St. Joseph Mercy Oakland
 Philip Stella, MD
Ph: 734-712-1000
  Port Huron
 Mercy Regional Cancer Center at Mercy Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Clinical Trials Office - Seton Cancer Institute - Saginaw
Ph: 989-776-8411
  Saint Joseph
 Oncology Care Associates, PLLC
 Eric Lester, MD
Ph: 269-985-0029
  Southfield
 Providence Cancer Institute at Providence Hospital - Southfield Campus
 Anibal Drelichman, MD, MPH, FACP
Ph: 313-552-0620
  Warren
 St. John Macomb Hospital
 Philip Stella, MD
Ph: 734-712-1000
Minnesota
  Burnsville
 Fairview Ridges Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Edina
 Fairview Southdale Hospital
 Clinical Trials Office - Fairview Southdale Hospital
Ph: 612-625-3650
  Fridley
 Mercy and Unity Cancer Center at Unity Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Hutchinson
 Hutchinson Area Health Care
 Daniel Anderson
Ph: 320-234-5000
800-454-3903
  Lichfield
 Meeker County Memorial Hospital
 Clinical Trials Office - Meeker County Memorial Hospital
Ph: 320-693-4520
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Daniel Anderson
Ph: 651-232-7970
 Minnesota Oncology Hematology, PA - Maplewood
 Patrick Flynn, MD
Ph: 612-863-8585
  Minneapolis
 Hennepin County Medical Center - Minneapolis
 Clinical Trials Office - Hennepin County Medical Center - Minneapolis
Ph: 612-873-5911
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Clinical Trials Office - Virginia Piper Cancer Institute
Ph: 612-863-5654
  Robbinsdale
 Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
 Clinical Trials Office - Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
Ph: 763-520-1893
  Saint Louis Park
 CCOP - Metro-Minnesota
 Patrick Flynn, MD
Ph: 612-863-8585
 Park Nicollet Cancer Center
 Patrick Flynn, MD
Ph: 612-863-8585
  Saint Paul
 HealthEast Cancer Care at St. Joseph's Hospital
 Daniel Anderson
Ph: 651-232-7970
 United Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Shakopee
 St. Francis Cancer Center at St. Francis Medical Center
 Patrick Flynn, MD
Ph: 612-863-8585
  St. Paul
 Regions Hospital Cancer Care Center
 Clinical Trials Office - Regions Hospital Cancer Care Center
Ph: 651-254-1517
  Waconia
 Ridgeview Medical Center
 Patrick Flynn, MD
Ph: 612-863-8585
  Woodbury
 HealthEast Cancer Care at Woodwinds Health Campus
 Daniel Anderson
Ph: 651-232-7970
 Minnesota Oncology Hematology, PA - Woodbury
 Patrick Flynn, MD
Ph: 612-863-8585
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 Robert Hamilton
Ph: 601-984-5590
Missouri
  Springfield
 CCOP - Cancer Research for the Ozarks
 Robert Carolla
Ph: 417-269-4520
 Hulston Cancer Center at Cox Medical Center South
 Robert Carolla
Ph: 417-269-5257
 St. John's Regional Health Center
 Robert Carolla
Ph: 417-820-2000
Montana
  Billings
 Billings Clinic - Downtown
 Clinical Trials Office - Billings Clinic - Downtown
Ph: 800-996-2663
 Email: research@billingsclinic.org
 CCOP - Montana Cancer Consortium
 Benjamin Marchello, MD
Ph: 406-238-6290
 Hematology-Oncology Centers of the Northern Rockies - Billings
 Benjamin Marchello, MD
Ph: 406-238-6290
 Northern Rockies Radiation Oncology Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 St. Vincent Healthcare Cancer Care Services
 Benjamin Marchello, MD
Ph: 406-238-6290
  Butte
 St. James Healthcare Cancer Care
 Benjamin Marchello, MD
Ph: 406-238-6290
  Great Falls
 Benjamin Marchello, MD
Ph: 406-238-6290
 Great Falls Clinic - Main Facility
 Benjamin Marchello, MD
Ph: 406-238-6290
  Havre
 Northern Montana Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290
  Kalispell
 Glacier Oncology, PLLC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Medical Oncology at KRMC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Regional Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
  Missoula
 Community Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 Guardian Oncology and Center for Wellness
 Benjamin Marchello, MD
Ph: 406-238-6290
 Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
 Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Ph: 406-329-7029
 Montana Cancer Specialists at Montana Cancer Center
 Clinical Trials Office - Montana Cancer Specialists at Montana Cancer Center
Ph: 406-238-6962
New Jersey
  Marlton
 Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
 Clinical Trials Office - Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Ph: 888-847-8823
  Voorhees
 Fox Chase Virtua Health Cancer Program at Virtua West Jersey
 Michael Entmacher, MD
Ph: 609-702-1900
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Clinical Trials Office - University of New Mexico Cancer Center
Ph: 505-272-6972
New York
  Bronx
 Our Lady of Mercy Medical Center Comprehensive Cancer Center
 Peter Wiernik, MD
Ph: 718-304-7200
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  East Syracuse
 CCOP - Hematology-Oncology Associates of Central New York
 Jeffrey Kirshner, MD
Ph: 315-472-7504
  Glens Falls
 Charles R. Wood Cancer Center at Glens Falls Hospital
 Clinical Trials Office - Charles R. Wood Cancer Center at Glens Falls Hospital
Ph: 518-926-6700
  Middletown
 Tucker Center for Cancer Care at Orange Regional Medical Center
 Clinical Trials Office - Tucker Center for Cancer Care at Orange Regional Medical Center
Ph: 845-342-7609
  Rochester
 Highland Hospital of Rochester
 Richard Fisher, MD
Ph: 585-275-0842
 Interlakes Oncology/Hematology PC
 Richard Fisher, MD
Ph: 585-275-0842
 James P. Wilmot Cancer Center at University of Rochester Medical Center
 Richard Fisher, MD
Ph: 585-275-0842
North Carolina
  Asheboro
 Randolph Hospital
 Clinical Trails Office - Randolph Hospital
Ph: 336-832-0821
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Goldsboro
 Wayne Memorial Hospital, Incorporated
 James Atkins, MD
Ph: 919-580-0000
  Greensboro
 Moses Cone Regional Cancer Center at Wesley Long Community Hospital
 Clinical Trials Office - Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Ph: 336-621-8374
  Kinston
 Kinston Medical Specialists
 Peter Watson, MD
Ph: 252-559-2200ext.201
  Reidsville
 Annie Penn Cancer Center
 Clinical Trials Office - Annie Penn Cancer Center
Ph: 336-621-8374
  Rutherfordton
 Rutherford Hospital
 James Bearden, MD
Ph: 864-560-6812
North Dakota
  Bismarck
 Bismarck Cancer Center
 Edward Wos, DO
Ph: 701-323-5741
 Medcenter One Hospital Cancer Care Center
 Edward Wos, DO
Ph: 701-323-5741
 Mid Dakota Clinic, PC
 Clinical Trials Office - Mid Dakota Clinic, PC
Ph: 701-530-6950
 St. Alexius Medical Center Cancer Center
 Clinical Trials Office - St. Alexius Medical Center Cancer Center
Ph: 701-530-6950
Ohio
  Bellefontaine
 Mary Rutan Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Bowling Green
 Wood County Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Chillicothe
 Adena Regional Medical Center
 Clinical Trials Office - Adena Regional Medical Center
Ph: 877-779-7585
  Cincinnati
 Charles M. Barrett Cancer Center at University Hospital
 Leslie Oleksowicz
Ph: 513-584-3200
888-640-CARE
  Cleveland
 Cleveland Clinic Taussig Cancer Center
 Clinical Trials Office - Cleveland Clinic Taussig Cancer Center
Ph: 866-223-8100
  Clyde
 North Coast Cancer Care - Clyde
 Paul Schaefer, MD
Ph: 419-479-5605
  Columbus
 CCOP - Columbus
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Doctors Hospital at Ohio Health
 Clinical Trials Office - Doctors Hospital at Ohio Health
Ph: 614-566-3275
 Grant Medical Center Cancer Care
 Clinical Trials Office - Grant Medical Center Cancer Care
Ph: 614-566-4475
 Mount Carmel Health - West Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Riverside Methodist Hospital Cancer Care
 Clinical Trials Office - Riverside Methodist Hospital Cancer Care
Ph: 614-566-4475
  Dayton
 CCOP - Dayton
 Howard Gross, MD
Ph: 937-832-1093
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
 Good Samaritan Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Grandview Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Samaritan North Cancer Care Center
 Howard Gross, MD
Ph: 937-832-1093
 Veterans Affairs Medical Center - Dayton
 Howard Gross, MD
Ph: 937-832-1093
  Delaware
 Grady Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Elyria
 Hematology Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Findlay
 Blanchard Valley Medical Associates
 Howard Gross, MD
Ph: 937-832-1093
  Franklin
 Middletown Regional Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Greenville
 Wayne Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Kettering
 Charles F. Kettering Memorial Hospital
 Clinical Trials Office - Charles F. Kettering Memorial Hospital
Ph: 937-298-3399 ext. 57556
  Lancaster
 Fairfield Medical Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Lima
 Lima Memorial Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Rita's Medical Center
 Clinical Trials Office - St. Rita's Medical Center
Ph: 419-226-9617
  Marietta
 Strecker Cancer Center at Marietta Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Maumee
 Northwest Ohio Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Luke's Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Newark
 Licking Memorial Cancer Care Program at Licking Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Oregon
 St. Charles Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic - Oregon
 Paul Schaefer, MD
Ph: 419-479-5605
  Sandusky
 North Coast Cancer Care, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Springfield
 Community Hospital of Springfield and Clark County
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Mercy Medical Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Sylvania
 Flower Hospital Cancer Center
 Clinical Trials Office - Flower Hospital Cancer Center
Ph: 419-824-1842
  Tiffin
 Mercy Hospital of Tiffin
 Paul Schaefer, MD
Ph: 419-479-5605
  Toledo
 CCOP - Toledo Community Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Medical University of Ohio Cancer Center
 Clinical Trials Office - Medical University of Ohio Cancer Center
Ph: 419-383-6583
 St. Anne Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Vincent Mercy Medical Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic, Incorporated - Main Clinic
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Hospital
 Clinical Trials Office - Toledo Hospital
Ph: 419-824-1842
  Troy
 UVMC Cancer Care Center at Upper Valley Medical Center
 Clinical Trials Office - UVMC Cancer Care Center at Upper Valley Medical Center
Ph: 937-440-4842
  Wauseon
 Fulton County Health Center
 Clinical Trials Office - Fulton County Health Center
Ph: 419-330-2708
  Westerville
 Mount Carmel St. Ann's Cancer Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Wilmington
 Clinton Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Xenia
 Ruth G. McMillan Cancer Center at Greene Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Zanesville
 Genesis - Good Samaritan Hospital
 Clinical Trials Office - Genesis - Good Samaritan Hospital
Ph: 740-454-5232
Oklahoma
  Oklahoma City
 Integris Oncology Services
 Chris Davis, MD
Ph: 405-949-3870
Oregon
  Gresham
 Legacy Mount Hood Medical Center
 Clinical Trials Office - Legacy Mount Hood Medical Center
Ph: 503-413-2150
  Milwaukie
 Providence Milwaukie Hospital
 Keith Lanier, MD
Ph: 503-299-6500
  Portland
 Adventist Medical Center
 Keith Lanier, MD
Ph: 503-299-6500
 CCOP - Columbia River Oncology Program
 Keith Lanier, MD
Ph: 503-299-6500
 Knight Cancer Institute at Oregon Health and Science University
 Clinical Trials Office - Knight Cancer Institute at Oregon Health and Science University
Ph: 503-494-1080
 Email: trials@ohsu.edu
 Legacy Emanuel Hospital and Health Center and Children's Hospital
 Clinical Trials Office - Legacy Emanuel Hospital and Health Center and Children's Hospital
Ph: 503-413-8199
 Legacy Good Samaritan Hospital & Comprehensive Cancer Center
 Clinical Trials Office - Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Ph: 503-413-1742
 Providence Cancer Center at Providence Portland Medical Center
 Clinical Trials Office - Providence Cancer Center at Providence Portland Medical Center
Ph: 503-215-6412
 Providence St. Vincent Medical Center
 Clinical Trials Office - Providence St. Vincent Medical Center
Ph: 503-215-6412
  Salem
 Salem Hospital Regional Cancer Care Services
 Clinical Trials Office - Salem Hospital Regional Cancer Care Services
Ph: 503-561-2618
  Tualatin
 Legacy Meridian Park Hospital
 Clinical Trials Office - Legacy Meridian Park Hospital
Ph: 503-413-1742
Pennsylvania
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Clinical Trials Office - Geisinger Cancer Institute
Ph: 570-271-5251
  Hazleton
 Geisinger Hazleton Cancer Center
 Albert Bernath, MD
Ph: 570-214-9290
  Philadelphia
 Fox Chase Cancer Center - Philadelphia
 Clinical Trials Office - Fox Chase Cancer Center - Philadelphia
Ph: 215-728-4790
  State College
 Geisinger Medical Group - Scenery Park
 Albert Bernath, MD
Ph: 570-214-9290
  Wilkes-Barre
 Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
 Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Ph: 570-271-5251
 Mercy Hospital at Wilkes-Barre
 Albert Bernath, MD
Ph: 570-214-9290
South Carolina
  Anderson
 AnMed Cancer Center
 Clinical Trials Office - AnMed Cancer Center
Ph: 864-512-1000
  Spartanburg
 CCOP - Upstate Carolina
 Clinical Trials Office - CCOP - Upstate Carolina
Ph: 800-486-5941
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 Clinical Trials Office - Gibbs Regional Cancer Center
Ph: 800-486-5941
South Dakota
  Rapid City
 Rapid City Regional Hospital
 Richard Tenglin
Ph: 605-719-2360
Tennessee
  Kingsport
 Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
 Clinical Trials Office - Christine LaGuardia Phillips Cancer Center
Ph: 423-224-5593
  Knoxville
 Thompson Cancer Survival Center
 Clinical Trials Office - Thompson Cancer Survival Center
Ph: 865-541-1812
Texas
  San Antonio
 Cancer Therapy and Research Center
 Clinical Trials Office - Cancer Therapy and Research Center
Ph: 210- 616-5798
 University Hospital - San Antonio
 Dorothy Nguyen
Ph: 210-358-4000
 University of Texas Health Science Center at San Antonio
 Dorothy Nguyen
Ph: 210-567-4777
 Veterans Affairs Medical Center - San Antonio (Murphy)
 Dorothy Nguyen
Ph: 210-617-5300
Virginia
  Danville
 Danville Regional Medical Center
 Clinical Trials Office - Danville Regional Medical Center
Ph: 434-799-3753
  Fredericksburg
 Fredericksburg Oncology, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Martinsville
 Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County
 Arthur Sleeper, MD
Ph: 276-666-7200
  Norton
 Southwest Virginia Regional Cancer Center at Wellmonth Health
 Malcolm Mathews, MD
Ph: 423-224-3150
Washington
  Bellingham
 St. Joseph Cancer Center
 Saul Rivkin, MD
Ph: 206-386-2441
  Bremerton
 Olympic Hematology and Oncology
 Saul Rivkin, MD
Ph: 206-386-2441
  Kennewick
 Columbia Basin Hematology
 Saul Rivkin, MD
Ph: 206-386-2441
  Seattle
 Fred Hutchinson Cancer Research Center
 Saul Rivkin, MD
Ph: 206-386-2441
 Group Health Central Hospital
 Clinical Trials Office - Group Health Central Hospital
Ph: 206-287-2900
 Harborview Medical Center
 Saul Rivkin, MD
Ph: 206-386-2441
 Minor and James Medical, PLLC
 Saul Rivkin, MD
Ph: 206-386-2441
 Polyclinic First Hill
 Saul Rivkin, MD
Ph: 206-386-2441
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Saul Rivkin, MD
Ph: 206-386-2441
 University Cancer Center at University of Washington Medical Center
 Clinical Trials Office - University Cancer Center at University of Washington Medical Center
Ph: 206-616-8289
  Spokane
 Cancer Care Northwest - Spokane South
 Clinical Trials Office - Cancer Care Northwest - Spokane South
Ph: 509-228-1083
  Vancouver
 Southwest Washington Medical Center Cancer Center
 Keith Lanier, MD
Ph: 503-299-6500
West Virginia
  Charleston
 West Virginia University Health Sciences Center - Charleston
 Steven Jubelirer, MD
Ph: 304-388-8380
Wisconsin
  Eau Claire
 Center for Cancer Treatment & Prevention at Sacred Heart Hospital
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
 Marshfield Clinic Cancer Care at Regional Cancer Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  La Crosse
 Gundersen Lutheran Center for Cancer and Blood
 Clinical Trials Office - Gundersen Lutheran Cancer Center
Ph: 608-775-2385
 Email: cancerctr@gundluth.org
  Marshfield
 Marshfield Clinic - Marshfield Center
 Clinical Trials Office - Marshfield Clinic - Marshfield Center
Ph: 800-782-1581 ext. 94457
 Saint Joseph's Hospital
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Minocqua
 Marshfield Clinic - Lakeland Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Rhinelander
 Ministry Medical Group at Saint Mary's Hospital
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Rice Lake
 Marshfield Clinic - Indianhead Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Stevens Point
 Saint Michael's Hospital Cancer Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Wausau
 Marshfield Clinic - Wausau Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Weston
 Marshfield Clinic - Weston Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426
  Wisconsin Rapids
 Marshfield Clinic - Wisconsin Rapids Center
 Mohammad Khan, MD, FACP
Ph: 715-387-5426

Related Information

Featured trial article

Registry Information
Official Title A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Trial Start Date 2008-04-15
Trial Completion Date 2014-04-30 (estimated)
Registered in ClinicalTrials.gov NCT00324987
Date Submitted to PDQ 2006-04-18
Information Last Verified 2009-04-24
NCI Grant/Contract Number CA32102

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov